PRAXIS PRECISION MEDICINES, INC. Cash and Cash Equivalents, Fair Value Disclosure
PRAXIS PRECISION MEDICINES, INC. (PRAX) had Cash and Cash Equivalents, Fair Value Disclosure of $79.24 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $79.24M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $195.30M.
- 2024-12-31: Cash and Cash Equivalents, Fair Value Disclosure $128.65M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $79.24M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $195.30M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $128.65M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |